TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$30 Million

Mast Therapeutics

At-the-market Offering

Developer of novel, clinical-stage therapies created for serious or life-threatening diseases with significant unmet needs. The company's novel, clinical-stage therapies are focused on developing new treatment products for respiratory diseases, sickle cell, genetic disorder classified as a rare, or orphan disease and heart failure, a condition enabling patients to avail a high unmet need for innovative treatment options.